Our President and Chief Scientific Officer, Rachel Liberatore, attended the BIO International Convention in Boston last month. The event was a success, providing RenBio with valuable networking opportunities and eliciting an enthusiastic response to our revolutionary MYO Technology platform.

Dr. Liberatore had a great week engaging with a diverse array of potential collaborators and industry experts. The conference offered an ideal environment for establishing potential partnerships that will drive RenBio’s innovative initiatives forward.

RenBio remains focused on forging strategic collaborations and partnerships to accelerate the development and commercialization of MYO Technology. We look forward to capitalizing on the momentum gained at BIO 2023 and continuing our mission to revolutionize DNA-based antibody and therapeutic protein delivery.